Cancer Treatment News and Research

RSS

FDA approves new treatment option for prostate cancer

Today is an exciting day for men with advanced prostate cancer and the millions of families and loved ones who are profoundly affected. Today a new prostate cancer treatment option, Provenge, was approved by the Food and Drug Administration.

30 Apr 2010

Incorporation of NexACT technology helps reduce dose of Å6 compound for ovarian cancer treatment

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that results from a pre-clinical study showed significant improvement in the delivery and half life of Å6, a proprietary peptide treatment for ovarian cancer currently in Phase 2 development by Angstrom Pharmaceuticals. Specifically, the incorporation of NexACT® enabled the dose of Å6 to be cut by half, or from twice per day to once per day delivered subcutaneously, while achieving the same level of efficacy in the mouse lung metastasis model.

29 Apr 2010

New report evaluating use of SBRT in lung cancer treatment released

The American Society for Radiation Oncology has released its Emerging Technology Committee's report evaluating the use of stereotactic body radiotherapy in lung cancer treatment.

29 Apr 2010

A new approach for treating neurological and degenerative disorders

In studies on cancer, heart disease, neurological disorders and other degenerative conditions, some scientists are moving away from the "nature versus nurture" debate, and are finding you're not a creature of either genetics or environment, but both - with enormous implications for a new approach to health.

29 Apr 2010

Three new biomarkers for ductal carcinoma in situ found

A new study of women who have been diagnosed with ductal carcinoma in situ (D.C.I.S.), may help personalize cancer treatment required by the women.

29 Apr 2010

Imaging costs for Medicare cancer patients on the rise

A study in the Journal of the American Medical Association analyzed data from Medicare cancer patients to determine the change in imaging use for this group.

29 Apr 2010

SBRT shows promise in treatment of lung, liver and spinal tumors: Clinical experts

Radiosurgical approaches to cancer treatment are showing promise in the treatment of lung, liver, and spinal tumors, according to four leading clinical experts who presented at a symposium in New York earlier this month.

28 Apr 2010

FXR can slow proliferation of tamoxifen-resistant breast cancer cells: Study

A receptor that is present in the nucleus of cells can, when activated, slow the growth of tamoxifen-resistant breast cancer cells, a new study found. The study built on the recent discovery that farnesoid X receptor — a nuclear receptor found mainly in the liver — is found in breast cancer tissue.

28 Apr 2010

NCCTG to conduct Phase II study of brostallicin in combination with cisplatin for mTNBC cancer

Cell Therapeutics, Inc. today announced that the North Central Cancer Treatment Group ("NCCTG") plans to conduct a Phase II study of brostallicin in combination with cisplatin in patients with metastatic triple-negative breast ("mTNBC") cancer, defined by tumors lacking expression of estrogen, progesterone receptors and without over-expression of HER2. Additionally, the majority of breast cancers that are associated with the susceptibility mutation (BRCA1) are of the triple-negative type.

28 Apr 2010

Concord Medical signs definitive agreement to acquire 100% equity interest in Tianjin Kangmeng Radiology

Concord Medical Services Holdings Limited, operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that its wholly-owned subsidiary, Shenzhen Aohua Medical Device Leasing Co., Ltd., has entered into a definitive agreement to acquire 100% of the equity interest in Tianjin Kangmeng Radiology Equipment Management Co., Ltd., a company that manages four radiotherapy and diagnostic imaging centers in Hebei province.

27 Apr 2010

FDA grants NexMed clearance for HCC Phase 2 trial for PrevOnco

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the U.S. Food & Drug Administration (FDA) has cleared the Company to proceed with the proposed Phase 2 trial of PrevOnco™, its proprietary cancer treatment for patients with advanced, unresectable hepatocellular carcinoma (HCC), or liver cancer. The FDA granted PrevOnco™ orphan drug status in August 2008, and in March 2010, NexMed filed its Investigational New Drug (IND) application for the product candidate.

27 Apr 2010

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

OSI Pharmaceuticals, Inc. announced today that it has completed enrollment in the RADIANT study, a Phase III clinical trial testing Tarceva (erlotinib) as an adjuvant therapy in patients with Stage IB-IIIA non-small cell lung cancer who have undergone surgery and have EGFR-positive tumors.

26 Apr 2010

Myths and facts about pediatric cancer

"Your child has cancer." They are words every parent can't imagine hearing.

24 Apr 2010

New hopes to improve cancer diagnosis and treatment for children

Motivated clinicians and an Internet connection combined with computers and e-mail access have the power to transform pediatric cancer treatment in the most remote corners of earth, according to a St. Jude investigator writing in a recent issue of The Lancet Oncology.

24 Apr 2010

Biological activity of Curis' CUDC-101 HDAC, EGFR and HER2 inhibitor published in Cancer Research

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that a research paper describing the biological activity of its HDAC, EGFR and HER2 inhibitor, CUDC-101, was published online in the journal Cancer Research and also will be published in an upcoming print version of the journal.

23 Apr 2010

Resonant activation can be a strategy against bacterial persistence: Virginia Tech biologist

A Virginia Tech biologist proposes to use a physics strategy called resonant activation to nudge dormant bacteria cells into a stage where they will be sensitive to antibiotics.

22 Apr 2010

LIJ Medical Center to acquire TrueBeam system for cancer treatment

In a promising development for cancer patients in the New York metropolitan area, the Long Island Jewish (LIJ) Medical Center Department of Radiation Medicine announced today that it will acquire an innovative new system called TrueBeam that offers a radically different approach to treating cancer with image-guided radiotherapy.

22 Apr 2010

Curis presents data on CU-906 compound designed to inhibit HDAC and PI3K/mTOR targets simultaneously

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that data provided in a presentation entitled, "Antitumor activity of single small molecule agent targeting PI3K/mTor and HDAC," were presented at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010, which is being held in Washington, DC April 17-21.

21 Apr 2010

Abbott's first-quarter worldwide pharmaceutical sales increases by 12.9%

Abbott today announced financial results for the first quarter ended March 31, 2010.

21 Apr 2010

EGFR levels may help early detection of breast cancer

Levels of epidermal growth factor receptor (EGFR) may be elevated in the blood of women within 17 months prior to their breast cancer diagnosis, according to findings presented at the American Association for Cancer Research 101st Annual Meeting 2010, held here April 17-21.

21 Apr 2010